MarketCapExport financials
Liminal BioSciences (LMNL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Liminal BioSciences Income Statement 2022-2011 | LMNL
Brief overview of revenue and earnings at Liminal BioSciences
The overview follows changes across a five-year period. The revenue attributed to Liminal BioSciences moved from 22.3 million Canadian dollars to 401 thousand Canadian dollars between the two endpoints. The five-year change reached −98.2%, while CAGR stood at −55.2%. The decline points to a contraction in the scale of the business.
The five-year EBITDA result moved by +100%: from −123 million Canadian dollars to 0 Canadian dollars. EBITDA expanded faster than the top line. EBITDA margin was −551.1% at the start and 0% at the end. The increased EBITDA share is a positive sign.
Across the five years, the net result shifted from −120 million Canadian dollars to 622 thousand Canadian dollars. The business moved out of a loss and ended the period with a profit.
What the figures show
Positive developments coexist with areas of weakness. The strongest signals are higher operating efficiency and net-income growth. The main areas of concern are weak sales momentum and a narrow EBITDA buffer. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Liminal BioSciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 2.65 M | 11.7 M | 133 M | 248 M | 876 M | 971 M | 1.03 B | 867 M | 612 M | 130 K | - |
Shares |
3.1 M | 3.02 M | 2.44 M | 16.1 M | 828 K | 796 K | 598 K | 571 K | 578 K | 490 K | 420 K | - |
Historical Prices |
- | 0.88 | 4.8 | 8.25 | 299 | 1.1 K | 1.8 K | 1.95 K | 1.98 K | 1.4 K | 457 | 113 |
Net Income |
622 K | 12.2 M | -119 M | -207 M | -238 M | -120 M | -101 M | -51 M | 5.94 M | -16.5 M | 230 K | -2.55 M |
Revenue |
401 K | 643 K | 724 K | 745 K | 24.6 M | 22.3 M | 16.4 M | 24.5 M | 23 M | 20.6 M | 23.3 M | 17.6 M |
Gross Profit |
- | - | 1.28 M | 2.14 M | -1.07 M | 29 M | 9.63 M | 16.3 M | 16 M | 14 M | 18 M | 15.7 M |
EBITDA |
- | - | -85.6 M | -213 M | -226 M | -123 M | -109 M | -57.3 M | -15.1 M | -16.3 M | 2 M | -930 K |
Operating Expenses |
- | - | 95.4 M | 120 M | 123 M | 152 M | 117 M | 66.8 M | 48.1 M | 27.1 M | 16.3 M | 17.2 M |
General and Administrative Expenses |
- | - | 38.6 M | 45.3 M | 29.4 M | 29.6 M | 29.3 M | 16.6 M | 12.1 M | 8.58 M | 5.97 M | 5.79 M |
Annual performance
Select metrics to display
All numbers in CAD currency
Quarterly Income Statement Liminal BioSciences
| 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
3.1 M | 3.1 M | - | 31 M | - | 3.02 M | - | 29.9 M | - | 2.44 M | - | 23.4 M | - | 16.1 M | - | 16.5 M | - | 828 K | - | - | - | 796 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-9.14 M | 622 K | - | -6.22 M | - | 12.2 M | - | -32.1 M | - | -119 M | - | -27.8 M | - | -207 M | - | -134 M | - | -238 M | - | - | - | -120 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | 401 K | - | - | - | 643 K | - | - | - | 724 K | - | 540 K | - | 745 K | - | 762 K | - | 24.6 M | - | - | - | 22.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | - | - | - | - | - | - | 38.6 M | - | 9.85 M | - | 45.3 M | - | 18 M | - | 29.4 M | - | - | - | 29.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in CAD currency
The income statement is one of the three key financial reports of a company Liminal BioSciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
Russia